Market Overview
Scope of the Report
Segmented by Drugs (by Category (Insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs), by sub-segment (Basal or Long-acting, Bolus or Fast-acting, Traditional Human Insulin Drugs, Insulin Biosimilars, GLP-1 Receptor Agonists, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors))and Devices( Management Devices (Insulin Pumps, Insulin Pens, Syringes, Cartridges, and Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose (Hospital and Personal use) and Continuous Glucose Monitoring)).
Key Market Trends
Sulfonylureas and Metformin combined market holds 70% of share in Canada Oral diabetes drugs segment
Monitoring Devices holds the highest market share in Canada Diabetes Devices Market
Competitive Landscape
Reasons to Purchase this report:
This product will be delivered within 2 business days.
- The Canada diabetes care devices market is expected to register a CAGR of about 5.9% during the forecast period (2019-2024).
- Monitoring devices are anticipated to dominate the market during the forecast period, owing to the rising prevalence of diabetes and an increase in the number of device users in the country.
- There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps.
- By Segment Type in devices, the monitoring devices occupy the highest market share of 57.9% for the year 2018. The Self-monitoring blood glucose devices occupy the highest market share with test strips being highest in volume.
Scope of the Report
Segmented by Drugs (by Category (Insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs), by sub-segment (Basal or Long-acting, Bolus or Fast-acting, Traditional Human Insulin Drugs, Insulin Biosimilars, GLP-1 Receptor Agonists, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors))and Devices( Management Devices (Insulin Pumps, Insulin Pens, Syringes, Cartridges, and Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose (Hospital and Personal use) and Continuous Glucose Monitoring)).
Key Market Trends
Sulfonylureas and Metformin combined market holds 70% of share in Canada Oral diabetes drugs segment
- Metformin holds 27% of the market share in Canada oral diabetes drugs
- Metformin has proved to be an effective medication for diabetes treatment when the diet is not enough to provide a healthy way of life. Rather than other drugs that stimulate the release of insulin, metformin increases the body's sensitivity to insulin, thus, helping in reducing a patient’s blood sugar level.
- Asia-Pacific holds the highest market share due to many generic players in Metformin market.
- Sulfonylureas hold the highest market in Canada oral diabetes drugs market, second-generation Sulfonylureas which have fewer side effects, include Glipizide (Glucotrol), Glyburide (Micronase, Glynase PresTabs, and DiaBeta), and the newest drug, Glimepiride (Amaryl). A single-dose, extended-release form of Glipizide called Glucotrol XL is also available.
Monitoring Devices holds the highest market share in Canada Diabetes Devices Market
- Self-monitoring Blood Glucose Devices holds 48.7% of the market share in Canada diabetes devices market.
- The personal-use glucometer is expected to see high sales in the future, owing to the rising awareness and reducing costs associated with the glucometer.
- Due to favourable healthcare insurance policies, the glucometer segment of the market studied is expected to witness high growth, during the forecast period.
- In 2018, test strips use in hospitals and clinics hold 76.7% market share, which. The hospital/clinic’s use of test strips is expected to increase at a CAGR of 7.84%, during the forecast period.
Competitive Landscape
- There have been constant innovations driven by manufacturers to compete in the market. The major players, such as Abbott and Medtronic, have undergone many mergers, acquisitions, and partnerships, to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies.
- The manufacturers of insulin delivery devices are spending a massive amount on the R&D of the devices. For example, Novo Nordisk partnered with Abbott Diabetes Care, which may help to enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible with FreeStyle Libre portfolio of products.
- Mega Blockbuster Lantus, manufactured by Sanofi, led the basal insulin field. Lantus generated global sales of more than USD 7 billion at its peak in 2014.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format.
- Report customization as per the client's requirements.
- 3 months of analyst support.
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 Market Segmentation
6 MARKET INDICATORS
7 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novo Nordisk A/S
- Sanofi Aventis
- Eli Lilly
- AstraZeneca
- Boehringer Ingelheim
- Bristol Myers Squibb
- Roche
- Abbott
- Johnson and Johnson (Lifescan)
- Arkray
- Ascensia Diabetes Care
- AgaMatrix Inc.
- Dexcom
- Medtronic
- Becton Dickinson
- Ypsomed Holding AG
- Terumo
- LMC Diabetes and Endocrinology
- Bayshore Health Care
- Express Scripts
- One Drop
- Telus Health
Methodology
LOADING...
